Aristotle Capital Boston’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.3M | Sell |
80,574
-16,860
| -17% | -$3M | 1.23% | 31 |
|
|
2026
Q1 | $16.8M | Buy |
97,434
+11,220
| +13% | +$2.08M | 1.04% | 31 |
|
|
2025
Q4 | $17.2M | Sell |
86,214
-9,134
| -10% | -$1.66M | 0.94% | 43 |
|
|
2025
Q3 | $14.9M | Sell |
95,348
-1,003
| -1% | -$159K | 0.77% | 57 |
|
|
2025
Q2 | $14.6M | Sell |
96,351
-8,129
| -8% | -$1.08M | 0.74% | 58 |
|
|
2025
Q1 | $15.7M | Sell |
104,480
-25,681
| -20% | -$4.31M | 0.79% | 53 |
|
|
2024
Q4 | $24M | Sell |
130,161
-14,550
| -10% | -$2.8M | 0.89% | 45 |
|
|
2024
Q3 | $28.5M | Sell |
144,711
-5,983
| -4% | -$1.24M | 0.94% | 46 |
|
|
2024
Q2 | $31.1M | Buy |
150,694
+2,115
| +1% | +$479K | 1.05% | 37 |
|
|
2024
Q1 | $40.3M | Sell |
148,579
-5,093
| -3% | -$1.22M | 1.22% | 26 |
|
|
2023
Q4 | $36.3M | Sell |
153,672
-5,232
| -3% | -$1.03M | 1.11% | 33 |
|
|
2023
Q3 | $31.1M | Sell |
158,904
-1,420
| -0.9% | -$292K | 1% | 39 |
|
|
2023
Q2 | $33.7M | Buy |
160,324
+3,594
| +2% | +$715K | 1.01% | 38 |
|
|
2023
Q1 | $31.6M | Buy |
156,730
+2,925
| +2% | +$663K | 0.98% | 37 |
|
|
2022
Q4 | $33.5M | Sell |
153,805
-4,353
| -3% | -$951K | 1.06% | 31 |
|
|
2022
Q3 | $31.1M | Sell |
158,158
-15,555
| -9% | -$3.36M | 1.05% | 29 |
|
|
2022
Q2 | $37.2M | Buy |
173,713
+814
| +0.5% | +$199K | 1.11% | 24 |
|
|
2022
Q1 | $49.1M | Sell |
172,899
-2,821
| -2% | -$870K | 1.24% | 19 |
|
|
2021
Q4 | $66.2M | Sell |
175,720
-46,963
| -21% | -$18.2M | 1.55% | 9 |
|
|
2021
Q3 | $91.9M | Sell |
222,683
-71,144
| -24% | -$29.5M | 2.16% | 2 |
|
|
2021
Q2 | $109M | Sell |
293,827
-31,855
| -10% | -$10.6M | 2.49% | 1 |
|
|
2021
Q1 | $94.4M | Sell |
325,682
-30,090
| -8% | -$8.36M | 2.1% | 1 |
|
|
2020
Q4 | $88.9M | Sell |
355,772
-49,555
| -12% | -$11.8M | 2.11% | 1 |
|
|
2020
Q3 | $91.8M | Buy |
405,327
+10,297
| +3% | +$2.14M | 2.66% | 1 |
|
|
2020
Q2 | $68.9M | Buy |
395,030
+34,978
| +10% | +$5.58M | 2.09% | 5 |
|
|
2020
Q1 | $45.4M | Sell |
360,052
-16,262
| -4% | -$2.44M | 1.94% | 7 |
|
|
2019
Q4 | $57.5M | Buy |
376,314
+8,032
| +2% | +$1.11M | 1.58% | 14 |
|
|
2019
Q3 | $48.7M | Buy |
368,282
+7,232
| +2% | +$970K | 1.43% | 14 |
|
|
2019
Q2 | $51.2M | Buy |
361,050
+12,853
| +4% | +$1.74M | 1.6% | 15 |
|
|
2019
Q1 | $50.6M | Buy |
348,197
+203,974
| +141% | +$26.8M | 1.69% | 10 |
|
|
2018
Q4 | $16.3M | Buy |
144,223
+18,271
| +15% | +$2.29M | 1.34% | 22 |
|
|
2018
Q3 | $16.9M | Buy |
125,952
+5,553
| +5% | +$685K | 1.24% | 24 |
|
|
2018
Q2 | $13.5M | Sell |
120,399
-125,460
| -51% | -$13.6M | 1.07% | 35 |
|
|
2018
Q1 | $26.2M | Buy |
245,859
+102,998
| +72% | +$11.1M | 1.23% | 22 |
|
|
2017
Q4 | $15.6M | Buy |
142,861
+32,747
| +30% | +$3.56M | 1.14% | 22 |
|
|
2017
Q3 | $11.9M | Buy |
110,114
+24,018
| +28% | +$2.47M | 1.07% | 30 |
|
|
2017
Q2 | $8.71M | Buy |
86,096
+19,168
| +29% | +$1.76M | 0.97% | 38 |
|
|
2017
Q1 | $6.02M | Buy |
66,928
+2,226
| +3% | +$189K | 0.8% | 57 |
|
|
2016
Q4 | $4.93M | Buy |
64,702
+13,148
| +26% | +$999K | 0.68% | 67 |
|
|
2016
Q3 | $4.3M | Buy |
51,554
+2,579
| +5% | +$216K | 0.77% | 65 |
|
|
2016
Q2 | $4.04M | Buy |
48,975
+808
| +2% | +$66.6K | 0.78% | 63 |
|
|
2016
Q1 | $3.66M | Buy |
48,167
+3,155
| +7% | +$234K | 0.73% | 70 |
|
|
2015
Q4 | $3.62M | Buy |
45,012
+6,684
| +17% | +$482K | 0.74% | 67 |
|
|
2015
Q3 | $2.44M | Buy |
38,328
+758
| +2% | +$54.4K | 0.59% | 76 |
|
|
2015
Q2 | $2.64M | Buy |
37,570
+10,579
| +39% | +$783K | 0.6% | 79 |
|
|
2015
Q1 | $2.14M | Buy |
26,991
+10,100
| +60% | +$745K | 0.67% | 74 |
|
|
2014
Q4 | $1.07M | Buy |
+16,891
| New | +$1.06M | 0.54% | 88 |
|
Other funds holding CRL
AI
Aristotle Capital Boston's CRL Position: Q2 2026 in Review
Aristotle Capital Boston reduced its Charles River Laboratories (CRL) stake by 17% in Q2 2026, selling an estimated $3M and leaving 80,574 shares worth $18.3M. The position accounts for 1.23% of the portfolio, ranked #31.
Aristotle Capital Boston first reported a position in CRL in Q4 2014 and has held it in 47 quarters since. The position peaked at $109M in Q2 2021. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Aristotle Capital Boston held 80,574 shares of Charles River Laboratories worth $18.3M as of Q2 2026.
- Aristotle Capital Boston sold 16,860 Charles River Laboratories shares in Q2 2026, an estimated $3M.
- Charles River Laboratories made up 1.23% of Aristotle Capital Boston's portfolio in Q2 2026, its #31 holding.
- Aristotle Capital Boston first reported a position in Charles River Laboratories in Q4 2014 and has held it in 47 quarters since.
- Aristotle Capital Boston's Charles River Laboratories position peaked at $109M in Q2 2021.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Aristotle Capital Boston's 13F filing for Q2 2026, filed 14 Aug 2026.